These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
164 related articles for article (PubMed ID: 15006189)
1. Therapeutic drug monitoring of antiretroviral therapy. Rakhmanina NY; van den Anker JN; Soldin SJ AIDS Patient Care STDS; 2004 Jan; 18(1):7-14. PubMed ID: 15006189 [TBL] [Abstract][Full Text] [Related]
2. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy. Van Vaerenbergh K Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503 [TBL] [Abstract][Full Text] [Related]
3. HIV therapeutics: points from the recent literature. Laurence J AIDS Read; 2003 Jul; 13(7):305, 307. PubMed ID: 12889448 [No Abstract] [Full Text] [Related]
4. Clinical benefit of interventions driven by therapeutic drug monitoring. Rendón A; Núñez M; Jiménez-Nácher I; González de Requena D; González-Lahoz J; Soriano V HIV Med; 2005 Sep; 6(5):360-5. PubMed ID: 16156885 [TBL] [Abstract][Full Text] [Related]
5. Position paper on therapeutic drug monitoring of antiretroviral agents. Acosta EP; Gerber JG; AIDS Res Hum Retroviruses; 2002 Aug; 18(12):825-34. PubMed ID: 12201904 [TBL] [Abstract][Full Text] [Related]
6. [Consensus document of Gesida and Spanish Secretariat for the National Plan on AIDS (SPNS) regarding combined antiretroviral treatment in adults infected by the human immunodeficiency virus (January 2012)]. Panel de expertos de Gesida y Plan Nacional sobre el Sida Enferm Infecc Microbiol Clin; 2012 Jun; 30(6):e1-89. PubMed ID: 22633764 [TBL] [Abstract][Full Text] [Related]
7. Benefits and Limits of Antiretroviral Drug Monitoring in Routine Practice. Maitre T; Muret P; Blot M; Waldner A; Duong M; Si-Mohammed A; Chavanet P; Aho S; Piroth L Curr HIV Res; 2019; 17(3):190-197. PubMed ID: 31490758 [TBL] [Abstract][Full Text] [Related]
8. Monitoring of HIV viral load, CD4 cell count, and clinical assessment versus clinical monitoring alone for antiretroviral therapy in low-resource settings (Stratall ANRS 12110/ESTHER): a cost-effectiveness analysis. Boyer S; March L; Kouanfack C; Laborde-Balen G; Marino P; Aghokeng AF; Mpoudi-Ngole E; Koulla-Shiro S; Delaporte E; Carrieri MP; Spire B; Laurent C; Moatti JP; Lancet Infect Dis; 2013 Jul; 13(7):577-86. PubMed ID: 23602084 [TBL] [Abstract][Full Text] [Related]
9. Therapeutic drug monitoring in HIV treatment: a literature review. Wertheimer BZ; Freedberg KA; Walensky RP; Yazdanapah Y; Losina E HIV Clin Trials; 2006; 7(2):59-69. PubMed ID: 16798621 [TBL] [Abstract][Full Text] [Related]
10. Long-term suppression of plasma viremia with highly active antiretroviral therapy despite virus evolution and very limited selection of drug-resistant genotypes. Pariente N; Pernas M; de la Rosa R; Gómez-Mariano G; Fernández G; Rubio A; López M; Benito JM; López-Galíndez C; Leal M; Domingo E; Martinez MA; Mas A J Med Virol; 2004 Jul; 73(3):350-61. PubMed ID: 15170628 [TBL] [Abstract][Full Text] [Related]
11. The advantages of therapeutic drug monitoring in patients receiving antiretroviral treatment and experiencing medication-related problems. Schoenenberger JA; Aragones AM; Cano SM; Puig T; Castello A; Gomez-Arbones X; Porcel JM Ther Drug Monit; 2013 Feb; 35(1):71-7. PubMed ID: 23188184 [TBL] [Abstract][Full Text] [Related]
12. Preventing and managing antiretroviral drug resistance. Kuritzkes DR AIDS Patient Care STDS; 2004 May; 18(5):259-73. PubMed ID: 15186710 [TBL] [Abstract][Full Text] [Related]
13. Beyond first-line HIV treatment regimens: the current state of antiretroviral regimens, viral load monitoring, and resistance testing in resource-limited settings. Kumarasamy N; Krishnan S Curr Opin HIV AIDS; 2013 Nov; 8(6):586-90. PubMed ID: 24100872 [TBL] [Abstract][Full Text] [Related]
15. [National consensus document by GESIDA/National Aids Plan on antiretroviral treatment in adults infected by the human immunodeficiency virus (January 2011 update)]. Panel de expertos de GESIDA y Plan Nacional sobre el Sida Enferm Infecc Microbiol Clin; 2011 Mar; 29(3):209.e1-103. PubMed ID: 21388714 [TBL] [Abstract][Full Text] [Related]
16. [Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update February 2009)]. Panel de expertos de Gesida y Plan Nacional sobre el Sida Enferm Infecc Microbiol Clin; 2009 Apr; 27(4):222-35. PubMed ID: 19246124 [TBL] [Abstract][Full Text] [Related]
17. Development of HIV with drug resistance after CD4 cell count-guided structured treatment interruptions in patients treated with highly active antiretroviral therapy after dual-nucleoside analogue treatment. Nuesch R; Ananworanich J; Sirivichayakul S; Ubolyam S; Siangphoe U; Hill A; Cooper D; Lange J; Phanuphak P; Ruxrungtham K Clin Infect Dis; 2005 Mar; 40(5):728-34. PubMed ID: 15714420 [TBL] [Abstract][Full Text] [Related]
18. Antiretroviral therapy for HIV: drug resistance and sequencing. Burkle WS J Assoc Nurses AIDS Care; 2002; 13(1):76-80. PubMed ID: 11828862 [No Abstract] [Full Text] [Related]
19. Therapeutic drug monitoring of antiretroviral drugs in HIV-infected patients. Punyawudho B; Singkham N; Thammajaruk N; Dalodom T; Kerr SJ; Burger DM; Ruxrungtham K Expert Rev Clin Pharmacol; 2016 Dec; 9(12):1583-1595. PubMed ID: 27626677 [TBL] [Abstract][Full Text] [Related]
20. Patients who want to stop their medications: treatment interruptions in HIV infection. Ball SC AIDS Read; 2003 Jul; 13(7):317-9, 324, 342. PubMed ID: 12889449 [No Abstract] [Full Text] [Related] [Next] [New Search]